Effects of irinotecan and 5-FU combination therapy in gastric cancer - Is combination therapy synergic?

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 11, 2010, Pages 2125-2129

  Yamada, Takeshi ^a   Furukawa, Kiyonori ^a   Yokoi, Kimiyoshi ^a   Mamada, Yasuhiro ^a   Kanazawa, Yoshikazu ^a   Uchida, Eiji ^b  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Chemotherapy; Combination index; Gastric cancer

Indexed keywords

COLLAGEN GEL; FLUOROURACIL; IRINOTECAN;

ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; MONOTHERAPY; STOMACH CANCER;

EID: 79961205828     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Pozzo C, Barone C, Szanto J, et al: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15: 1773-1781, 2004. (Pubitemid 40017161)
2. Boku N, Ohtsu A, Shimada Y, et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17: 319-323, 1999. (Pubitemid 29022409)
3. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
4. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
5. Fukushima M, Fujioka A, Uchida F, et al: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to S-fluorouracil (s-FU) in human cancer xenografts in vivo. Eur J Cancer 37: 1681-1687, 2001. (Pubitemid 32778616)
6. Takiuchi H, Narahara H, Tsujinaka T, et al: Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). Jpn J Clin Oncol 35: 520-525, 2005. (Pubitemid 41573941)
7. Inokuchi M, Yamashita T, Yamada H, et al: Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 94: 1130-1135, 2006.
8. Kobayashi Y, Tanisaka K, and Doi O: An in vitro chemosensitivity test for solid tumors using collagen gel droplet embedded cultures. Int J Oncol 11: 449-455, 1997. (Pubitemid 27364274)
9. Gamelin E, Delva R, Jacob J, et al: Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. JCO 26: 2099-2105, 2008.
10. Mans DR, Grivicich I, Peters GJ, et al: Sequence dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 35: 1851-1861, 1999.
11. Dank M, Zaluski J, Barone C, et al: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naïve patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19: 1450-1457, 2008.
12. Imamura H, Iishi H, Tsuburaya A, et al: Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GCO301/TOP-002). Proc ASCO-Gl (abstr 5), 2008.
13. Uedo N, Narahara H, Ishihara R, et al: Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 73: 65-71, 2007. (Pubitemid 351465602)